Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Pain is the result of potential tissue damage which leads to an unbearable sensory and emotional experience. The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics and other non-narcotic analgesics.

The global pain management therapeutics market is estimated to be valued at US$ 75,976.0 million in 2021 and is expected to exhibit a CAGR of 3.6% over the forecast period (2021-2028).

Recent Developments:

Companies are publishing studies on alternative pain management therapeutics for replacing the use of opioids which can be attributed to drive the market growth. For instance, in July 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company published new analysis evaluating the efficacy and safety of ZYNRELEF. It is an extended-release solution of bupivacaine and meloxicam for producing postsurgical analgesia for up to 72 hours after bunionectomy.

In addition, companies are developing new candidates for pain management which is further boosting the market growth. For instance, in July 2021, Sorrento Therapeutics announced U.S. FDA approval for Phase 2 testing of its pain management candidate resiniferatoxin (RTX) which is used for treating moderate-to-severe osteoarthritis.

Moreover, the increasing number of patients requiring surgeries such as orthopedic, trauma and general surgeries is growing which is aid in boosting the market growth through the forecast period. For instance, according to the Australian Institute of Health and Welfare, compared to 2014–15 the admissions from public hospital elective surgery waiting lists increased, by an average of 2.1% per year in 2018–19.  

North America held dominant position in the global pain management therapeutics market in 2020, accounting for 32.40% share in terms of volume, followed by Europe and Asia Pacific, respectively. Companies operating in North America are extensively engaged in R&D activities for developing new pain management drugs which can be attributed to the dominant position of the region in the market. For instance, January 2021, Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company recently completed Phase 2 clinical trial of vocacapsaicin (CA-008), a first-in-class, non-opioid therapeutic with FDA Breakthrough Therapy Designation.

Figure 1. Global Pain Management Therapeutics Market Value (US$ Mn), by Region, 2020

Pain Management Therapeutics  | Coherent Market Insights

Global Pain Management Therapeutics Market: Drivers

Approval and launch of new therapeutics is expected to propel growth of the global pain management therapeutics market over the forecast period. For instance, in November 2018, AcelRx Pharmaceuticals, Inc. received approval for DSUVIA for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opioid analgesic, from the U.S. FDA.

Moreover, increasing prevalence of arthritis is also expected to aid in growth of the market. For instance, according to the Centers for Disease Control and Prevention (CDC)’s May 2019 report, an estimated 54.4 million US adults have diagnosed arthritis, which accounted for around 1 in 4 people in the U.S.

Global Pain Management Therapeutics Market: Opportunities 

R&D in alternatives for opioids is expected to offer lucrative growth opportunities for players in the global pain management therapeutics market. For instance, in June 2020, researchers at The University of Texas at Tyler, U.S., reported assessing the antinociceptive effects of 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrazol-4-yl)isoxazole, a novel positive allosteric modulator, with preferential selectivity to the low agonist sensitivity (α4)3(β2)2 Neuronal nicotinic acetylcholine receptor and desformylflustrabromine, a positive allosteric modulator for α4-containing neuronal nicotinic acetylcholine receptor.

Moreover, use of VR in pain management is also expected to aid in growth of the market. For instance, HTC Corporation’s HTC VIVE, a VR system is under clinical trial for assessing the effect of virtual reality technology on decreasing the acute pain of scar treatment with fractional laser under local anesthesia. The study is expected to be completed in December 2020.

request-sample

Pain Management Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 75,976.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.6% 2028 Value Projection: US$ 97,041.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Pain Type: Chronic, Acute
  • By Drug Class: NSAIDS, Anesthetics, Anticonvulsant, Anti-migraine Drugs, Antidepressant Drugs, Opioids, Non-narcotics, Analgesics
  • By Indication: Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, Others
Companies covered:

AcelRx Pharmaceuticals, Inc. Averitas Pharma, Inc., AmerisourceBergen, Cardinal Health, McKesson Corporation, Johnson & Johnson, Teva Pharmaceuticals, Abbott Laboratories, Allergan, Inc., Covidien plc, Durect Corporation, Eli Lilly and Company, Endo Health Solutions, Inc., Forest Laboratories, Inc., GlaxoSmithKline plc, Hospira, Inc., Merck & Co., Inc., Mundipharma International Ltd., and Novartis  International AG

Growth Drivers:
  • Approval and launch of new therapeutics
  • Increasing prevalence of arthritis
Restraints & Challenges:
  • Prescription drug abuse
  • Pain advocacy groups losing power, influence, and funding

Market Trends

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in December 2019, Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc., announced that the U.S. Food and Drug Administration (FDA) set a goal date under the Prescription Drug User Fee Act (PDUFA) of July 19, 2020 for QUTENZA for the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

Several market players have faced lawsuits regarding opioid crisis. For instance, in March 2019, Purdue Pharma reached a US$ 270 million settlement in a lawsuit, which claimed its opioids contributed to the deaths of thousands of people.

Figure 2. Global Pain Management Therapeutics Market Share, By Pain Type, 2020

Pain Management Therapeutics  | Coherent Market Insights

Key Takeaways of the Graph:

  • Among pain type, the acute held dominant position in the market and accounted for 54.5% share in the global pain management therapeutics market in 2020. The segment is expected to reach US$ 52,887.86 million in 2028.
  • The enforcement of new guidelines by international healthcare organization for efficient management of acute pain can be attributed to the segment growth. For instance, in November 2020, the American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP) revised the guidelines for management of acute pain of non–low back, and other musculoskeletal injuries in adults in the outpatient setting. The guidelines covered several recommendations such as use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line therapy and conditional use of opioids.
  • Among pain type, the chronic is expected to grow with the fastest CAGR of 3.9% over the forecast period.
  • The expansion of product portfolio through business development strategies such as acquisition, agreements and collaboration is expected to drive the growth of chronic segment through the forecast period. For instance, in January 2021, Eli Lilly and Company announced acquisition agreement with Asahi Kasei Pharma Corporation for AK1780. AK1780 is an orally bioavailable P2X7 receptor antagonist which has completed phase 1 and is used for treating patients with chronic pain conditions.

Global Pain Management Therapeutics Market: Restraints

Prescription drug abuse is expected to hinder growth of the market. For instance, according to the study, ‘ The Future of Fentanyl and Other Synthetic Opioids,’ published by RAND Corporation in 2019,  the number of deaths involving synthetic opioids increased from 3,000 in 2013 to more than 30,000 in 2018, in the U.S.

Moreover, pain advocacy groups losing power, influence, and funding is also expected to limit the market growth. Advocacy groups for pain management are losing power and influence that they had initially, due to loss in funding from government as well as sponsors, which included pharmaceutical organizations.

Global Pain Management Therapeutics Market: Competitive Landscape

Major players operating in the global pain management therapeutics market include, AcelRx Pharmaceuticals, Inc. Averitas Pharma, Inc., AmerisourceBergen, Cardinal Health, McKesson Corporation, Johnson & Johnson, Teva Pharmaceuticals, Abbott Laboratories, Allergan, Inc., Covidien plc, Durect Corporation, Eli Lilly and Company, Endo Health Solutions, Inc., Forest Laboratories, Inc., GlaxoSmithKline plc, Hospira, Inc., Merck & Co., Inc., Mundipharma International Ltd., and Novartis  International AG.

Global Pain Management Therapeutics Market: Key Developments

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in November 2019, Q Biomed Inc. announced the U.S. FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG) to manufacture the company's Strontium-89 Chloride USP, a non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in July 2019, Harvest One Cannabis Inc. acquired Delivra Corp., a specialty biotechnology company that manufactures and sells transdermal delivery system platform for nerve pain, varicose veins, and other conditions.

Pain management is a broad branch of medical science that utilizes an interdisciplinary approach to easing the patient's suffering and enhancing the quality of life of patients with chronic pain. A common aim of pain management is reducing the use of narcotics or pain killers, relaxing the patients' lifestyle and providing education on stress and pain management. The use of pain management treatments in combination with a holistic approach to disease prevention and therapy is now recognized as an effective treatment approach for moderate to severe pain. Chronic pain can result from injury, disease or injury, or be the result of a disease such as cancer or Parkinson's disease.

Market Dynamics:

R&D of new therapeutics is expected to propel growth of the global pain management therapeutics market over the forecast period. For instance, in August 2021, Flexion Therapeutics, Inc. expanded the placebo-controlled trial of FX301, a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function, in patients undergoing bunionectomy.

Moreover, increasing number of pain management clinics is also expected to aid in growth of the market. For instance, in August 2021, QC Kinetix, a regenerative medicine company that offers a non-surgical alternative to pain relief, started a new location Birmingham.

Key features of the study:

  • This report provides in-depth analysis of the global pain management therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global pain management therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AcelRx Pharmaceuticals, Inc. Averitas Pharma, Inc., AmerisourceBergen, Cardinal Health, McKesson Corporation, Johnson & Johnson, Teva Pharmaceuticals, Abbott Laboratories, Allergan, Inc., Covidien plc, Durect Corporation, Eli Lilly and Company, Endo Health Solutions, Inc., Forest Laboratories, Inc., GlaxoSmithKline plc, Hospira, Inc., Merck & Co., Inc., Mundipharma International Ltd., and Novartis  International AG
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global pain management therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pain management therapeutics market

Detailed Segmentation:

  •  Global Pain Management Therapeutics Market, By Pain Type:
    • Chronic
    • Acute
  • Global Pain Management Therapeutics Market, By Drug Class:
    • NSAIDS
    • Anesthetics
  • Global Pain Management Therapeutics Market, By Region:
    • North America
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Pain Type
        • Chronic
        • Acute
      • By Drug Class
        • NSAIDS
        • Anesthetics
        • Anticonvulsant
        • Anti-migraine Drugs
        • Antidepressant Drugs
        • Opioids
        • Non-narcotics
        • Analgesics
      • By Indication
        • Arthritic Pain
        • Neuropathic Pain
        • Cancer Pain
        • Chronic Pain
        • Post-operative Pain
        • Migraine
        • Fibromyalgia
        • Bone Fracture
        • Muscle Sprain/Strain
        • Acute Appendicitis
        • Others
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AcelRx Pharmaceuticals, Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Averitas Pharma, Inc.
    • AmerisourceBergen
    • Cardinal Health
    • McKesson Corporation
    • Johnson & Johnson
    • Teva Pharmaceuticals
    • Abbott Laboratories
    • Allergan, Inc
    • Covidien plc
    • Durect Corporation
    • Eli Lilly and Company
    • Endo Health Solutions, Inc
    • Forest Laboratories, Inc.
    • GlaxoSmithKline plc
    • Hospira, Inc.
    • Merck & Co., Inc
    • Mundipharma International Ltd.
    • Novartis International AG

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Pain Type
      • Market Snippet, By Drug Class
      • Market Snippet, By Indication
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • Regulatory Scenario
    • PEST Analysis
    • Mergers and Acquisitions
  4. Global Pain Management Therapeutics Market, By Pain Type, 2020 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Chronic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Acute
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
  5. Global Pain Management Therapeutics Market, By Drug Class, 2020 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • NSAIDS
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Anesthetics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Anticonvulsant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Anti-migraine Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Antidepressant Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Opioids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Non-narcotics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
  6. Global Pain Management Therapeutics Market, By Indication, 2020 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Arthritic Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Neuropathic Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Cancer Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Chronic Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Post-operative Pain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Migraine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Fibromyalgia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Bone Fracture
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Muscle Sprain/Strain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Acute Appendicitis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2028, (US$ Million)
  7. Global Pain Management Therapeutics Market, By Region, 2020 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Pain Type, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Drug Class, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Indication, 2018 – 2028, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Company Profiles
      • AcelRx Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Averitas Pharma, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • AmerisourceBergen
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cardinal Health
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • McKesson Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Allergan, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Covidien plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Durect Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Endo Health Solutions, Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Forest Laboratories, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hospira, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mundipharma International Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis  International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 36 market data tables and 34 figures on “Pain Management Therapeutics Market - Global forecast to 2028”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.